Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain

N/A Completed NCT02822989

Summary

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune, inflammatory disease and musculoskeletal pain is one of the most common symptoms. This study will investigate whether transcutaneous stimulation of the vagus nerve will decrease lupus musculoskeletal pain. This study will additionally investigate the biologic effects of vagus nerve stimulation on inflammation. It will be the first clinical study using one of the body's own pathways of modulating the immune system and inflammatory response, the cholinergic anti-inflammatory pathway, in SLE.

Change in Musculoskeletal Pain From Baseline.

5 days · units on a scale

Percentage of Subjects With Treatment Emergent Adverse Events.

12 days · Participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
• Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
• Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
• Reducing Disparities in Medication Adherence in SLE — Duke University
• COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders — National Institute of Allergy and Infectious Diseases (NIAID)

All trials